With the Competition Board decision dated 08.02.2024 and numbered 24-07/121-M, it was decided that a preliminary inquiry should be conducted into the allegation that Novozymes Enzim Dış Ticaret Ltd. Şti. (NOVO TÜRKİYE) violated the Act no 4054 on the Protection of Competition in the industrial enzymes market through practices aimed at obstructing the activities of its competitors as well as through exclusionary practices. Within the framework of the information and documents acquired and the examinations conducted during the preliminary inquiry process, it was found that Novozymes A/S (NZ) and its subsidiaries (Novozymes Berlin GmbH, Novozymes France S.A.S, Novozymes North America) as well as NOVO TÜRKİYE, a subsidiary of NZ serving as its agent in Türkiye, all of which are active in the sales of industrial enzymes in Türkiye and are part of the same economic entity (together, NOVO),

• Were operating with a wide product portfolio in Türkiye in the market for the sale of industrial enzymes used in various sectors including foods, agriculture, homecare products, bioenergy, textiles, leather and paper,   
• Held dominant position in the market for the fungal alpha amylase enzyme, which is a required  product in the flour and bakery sector,
• Applied a discount system for their buyers in the flour and bakery enzymes sector, which was designed to create high-levels of loyalty and to potentially exclude competitors from the market,
• Were strongly suspected of abusing their dominant position through the relevant discount practices and violated Article 6 of the Act no 4054,

and an investigation has been launched with the Competition Board decision dated 28.03.2024 and numbered 24-15/313-M under Article 41 of the Act no 4054 in order to determine if NOVO violated Article 6 of the same Act.

Moreover, since it was found that the discount system implemented by NOVO could lead to irreparable damages, an interim measure decision has been taken under Article 9.4 of the Act no 4054, barring NOVO from applying discounts in the sales of the fungal alpha amylase enzyme to create loyalty in the buyers and from including any discounts, promotions, free product deliveries or campaigns when selling other types of enzymes together with the fungal alpha amylase enzyme in its new sales agreements to be signed until the final decision.